Lowdose spironolactone reduces blood pressure in patients with resistant hypertension and type 2 diabetes mellitus: A double blind randomized clinical trial

Journal of Hypertension

Volumn 31, Issue 10, 2013, Pages 2094-2102

  Oxlund, Christina S ^a   Henriksen, Jan E ^a   Tarnow, Lise ^b   Schousboe, Karoline ^c   Gram, Jeppe ^d   Jacobsen, Ib A ^a  

^a ODENSE UNIVERSITY HOSPITAL   (Denmark)

^b STENO DIABETES CENTER   (Denmark)

^c LILLEBAELT HOSPITAL   (Denmark)

^d ESBJERG HOSPITAL   (Denmark)

Author keywords

Ambulatory blood pressure monitoring; Randomized clinical trials; Resistant arterial hypertension; Spironolactone; Type 2 diabetes; Urinary albumin creatinine ratio

Indexed keywords

ALBUMIN; SPIRONOLACTONE; ALBUMINOID; ALDOSTERONE; ANTIHYPERTENSIVE AGENT;

ADULT; AMBULATORY MONITORING; ARTICLE; BLOOD PRESSURE REGULATION; CONTROLLED STUDY; DENMARK; DOUBLE BLIND PROCEDURE; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; GLYCEMIC CONTROL; HUMAN; HYPERKALEMIA; HYPOTENSION; KIDNEY FUNCTION; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN URINE LEVEL; PULSE PRESSURE; RANDOMIZED CONTROLLED TRIAL; RESISTANT HYPERTENSION; TREATMENT DURATION; TREATMENT OUTCOME; URINARY EXCRETION; AGED; BLOOD PRESSURE; BLOOD PRESSURE MONITORING; CHEMISTRY; CONTROLLED CLINICAL TRIAL; DIABETES MELLITUS; HYPERTENSION; METABOLISM; MIDDLE AGED;

ADULT; AGED; ALBUMINS; ALDOSTERONE; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; BLOOD PRESSURE MONITORING, AMBULATORY; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; SPIRONOLACTONE;

EID: 84884364545     PISSN: 02636352     EISSN: 14735598     Source Type: Journal    
DOI: 10.1097/HJH.0b013e3283638b1a     Document Type: Article

References (46)

1. Reboldi G, Gentile G, Manfreda VM, Angeli F, Verdecchia P. Tight blood pressure control in diabetes: evidence-based review of treatment targets in patients with diabetes. Curr Cardiol Rep 2012; 14:89-96.
2. Vijan S, Hayward RA. Treatment of hypertension in type 2 diabetes mellitus: blood pressure goals, choice of agents, and setting priorities in diabetes care. Ann Intern Med 2003; 138:593-602.
3. Ferrannini E, Cushman WC. Diabetes and hypertension: the bad companions. Lancet 2012; 380:601-610.
4. Shestedt T, Hansen TW, Richart T, Boggia J, Kikuya M, Thijs L, et al. Are blood pressure and diabetes additive or synergistic risk factors? Outcome in 8494 subjects randomly recruited from 10 populations. Hypertens Res 2011; 34:714-721.
5. Paulsen MS, Sondergaard J, Reuther L, Larsen PS, Munck AP, Larsen PV, et al. Treatment of 5413 hypertensive patients: a cross-sectional study. Fam Pract 2011; 28:599-607.
6. Mancia G, Laurent S, Agabiti-Rosei E, Ambrosioni E, Burnier M, Caulfield MJ, et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens 2009; 27:2121-2158.
7. de la Sierra A, Segura J, Banegas JR, Gorostidi M, de la Cruz JJ, Armario P, et al. Clinical features of 8295 patients with resistant hypertension classified on the basis of ambulatory blood pressure monitoring. Hypertension 2011; 57:898-902.
8. Kronborg CN, Hallas J, Jacobsen IA. Prevalence, awareness, and control of arterial hypertension in Denmark. J Am Soc Hypertens 2009; 3:19-24.
9. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, et al. 2007 Guidelines for Management of Arterial Hypertension: the task force for the management of arterial hypertension of the European Society of hypertension; and European Society of Cardiology. J Hypertens 2007; 25:1105-1187.
10. Calhoun DA, Jones D, Textor S, Goff DC, Murphy TP, Toto RD, et al. Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Circulation 2008; 117:510-526.
11. Clark D 3rd, Ahmed MI, Calhoun DA. Resistant hypertension and aldosterone: an update. Can J Cardiol 2012; 28:318-325.
12. Daugherty SL, Powers JD, Magid DJ, Tavel HM, Masoudi FA, Margolis KL, et al. Incidence and prognosis of resistant hypertension in hypertensive patients. Circulation 2012; 125:1635-1642.
13. Egan BM, Zhao Y, Axon RN, Brzezinski WA, Ferdinand KC. Uncontrolled and apparent treatment resistant hypertension in the United States, 1988-2008. Circulation 2011; 124:1046-1058.
14. Rios MT, Domingues-Sardina M, Ayala DE, Gomara S, Sineiro E, Pousa L, et al. Prevalence and clinical characteristics of isolated-office and true resistant hypertension determined by ambulatory blood pressure monitoring. Chronobiol Int 2013; 30:207-220.
15. Pierdomenico SD, Lapenna D, Bucci A, Di Tomaso R, Di Mascio R, Manenta BM, et al. Cardiovascular outcome in treated hypertensive patients with responder, masked, false resistant and true resistant hypertension. Am J Hypertens 2005; 18:1422-1428.
16. Shibata H, Itoh H. Mineralocorticoid receptor-associated hypertension and its organ damage: clinical relevance for resistant hypertension. Am J Hypertens 2012; 25:514-523.
17. Sartori M, Mascagna CLA, Realdi A, Macchini L, Ciccariello L, De Toni R, et al. Aldosterone and refractory hypertension: a prospective cohort study. Am J Hypertens 2006; 19:373-780.
18. Vaclavik J, Sedlak R, Plachy M, Navratil K, Plasek J, Jarkovsky J, et al. Addition of spironolactone in patients with resistant arterial hypertension (ASPIRANT): a randomized, double-blind, placebo-controlled trial. Hypertension 2011; 57:1069-1075.
19. Abolghasmi R, Taziki O. Efficacy of low dose spironolactone in chronic kidney disease with resistant hypertension. Saudi Kidney Dis Transpl 2011; 22:75-78.
20. Colussi G, Catena C, Sechi LA. Spironolactone, eplerenone and the new aldosterone blockers in endocrine and primary hypertension. J Hypertens 2012; 31:3-15.
21. Rogoza AN, Povlova TS, Sergeeva MV. Validation of A&D UA-767 device for the self-measurement of blood pressure. Blood Press Monit 2000; 5:227-231.
22. Gabriak Wai-Kwok Yip, Hung-Kwan SO, Tomlinson B, Wong SN, Sung RY. Validation of A&D TM-2430 upper-arm blood pressure monitor for ambulatory blood pressure monitoring in children and adolescents, according to the British Hypertension Society protocol. Blood Press Monit 2012; 17:76-79.
23. O'Brien E, Asmar R, Beilin L, Imai Y, Mancia G, Mengden T, et al., on behalf of the European Society of Hypertension Working Group on Blood Pressure Monitoring. Practice guidelines of the European Society of Hypertension for clinic, ambulatory and self blood pressure measurement. J Hypertens 2005; 23:697-701.
24. AS Levey JC, Coresh J, Greene T, Stevens LA, Zhang YL, Hendriksen S, et al. Using standardized serum creatinine values in modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med 2006; 145:247-265.
25. European Agency for the Evaluation of Medicinal, Products, Points to consider on multiplicity issues in clinical, trials. EMEA 2002 September 2002; http://www.emea.eu.in.t.
26. Calhoun DA. Hyperaldosteronism as a common cause of resistant hypertension. Annu Rev Med 2013; 64:233-247.
27. Chapman N, Dobson J, Wilson S, Dahlof B, Sever PS, Wedel H, Poulter NR. Effect of spironolactone on blood pressure in subjects with resistant hypertension. Hypertension 2007; 49:839-845.
28. Engbaek M, Hjerrild M, Hallas J, Jacobsen IA. The effect of low-dose spironolactone on resistant hypertension. J Am Soc Hypertens 2010; 4:290-294.
29. Lane DA, Shah S, Beevers DG. Low-dose spironolactone in the management of resistant hypertension: a surveillance study. J Hypertens 2007; 25:891-894.
30. Sharabi Y, Adler E, Shamis A, Nussinovitch N, Markovitz A, Grossman E. Efficacy of add-on aldosterone receptor blocker in uncontrolled hypertension. Am J Hypertens 2006; 19:750-755.
31. de Souza F, Muxfeldt E, Fiszman R, Salles G. Efficacy of spironolactone therapy in patients with true resistant hypertension. Hypertension 2010; 55:147-152.
32. Hansen TW, Li Y, Boggia J, de Thijs L, Richart T, Staessen JA. Predictive role of the nighttime blood pressure. Hypertension 2011; 57:3-10.
33. Graham I, Atar D, Borch-Johnsen K, Boysen G, Burell G, Cifkova R, et al. European guidelines on cardiovascular disease prevention in clinical practice: executive summary: Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (Constituted by representatives of nine societies and by invited experts). Eur Heart J 2007; 28:2375-2414.
34. Bangalore S, Kumar S, Lobach I, Messerli FH. Blood pressure targets in subjects with type 2 diabetes mellitus/impaired fasting glucose: observations from traditional and bayesian random-effects meta-analyses of randomized trials. Circulation 2011; 123:2799-2810.
35. Barzilay JI, Howard AG, Evans GW, Fleg JL, Cohen RM, Booth GL, et al. Intensive Blood Pressure treatment does not improve cardiovascular outcomes in centrally obese hypertensive individuals with diabetes: The Action to Control Cardiovascular Risk in Diabetes (ACCORD) Blood Pressure Trial. Diabetes care 2012; 35: 1401-1405.
36. Franklin SS, Thijs L, Li Y, Hansen TW, Boggia J, Liu Y, et al. Masked hypertension in diabetes mellitus. Hypertension 2013; 61:964-971.
37. Reboldi G, Gentile G, Angeli F, Ambrosio G, Mancia G, Verdecchia P. Effects of intensive blood pressure reduction on myocardial infarction and stroke in diabetes: A metaanalysis in 73913 patients. J Hypertens 2011; 29:1253-1269.
38. The ACCORD study group. Effects of intensive blood pressure control in Type 2 diabetes mellitus. N Engl J Med 2010; 362:1575-1585.
39. Rossing K, Schjoedt KJ, Smidt UM, Boomsma F, Parving HH. Beneficial effects of adding spironolactone to recommended antihypertensive treatment in diabetic nephropathy: a randomized, double-masked, cross-over study. Diabetes care 2005; 28:2106-2112.
40. Mann JF, Schmider RE, McQueen M, Dyal L, Schumacher H, Pogue J, et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vacular risk (the ONTARGET study): a multicentre, randomized, double-blind, controlled trial. Lancet 2008; 371:1575-1576.
41. Jeunemaitre X, Chatellier G, Kreft-Jais C, Charru A, DeVries C, Plouin PJ, et al. Efficacy and tolerance of spironolactone in essential hypertension. Am J Cardiol 1987; 60:820-926.
42. Esler MD, Krum H, Sobotka PA, Schlaich MP, Schmieder RE, Bohm M. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. Lancet 2010; 376:1903-1909.
43. Bisognano JD, Bakris G, Nadim MK, Sanchez L, Kroon AA, Schafer J, et al. Baroreflex activation therapy lowers blood pressure in patiants with resistant hypertension: results from the double blind, randomized, placebo-controlled Rheos pivotal trial. Am Coll Cardiol 2011; 58:765-773.
44. Bobrie G, Frank M, Azizi M, Peyrard S, Boutouyrie P, Chatellier G, et al. Sequential nephron blockade versus sequential renin-angiotensin system blockade in resistant hypertension: a prospective, randomized, open blinded endpoint study. J Hypertens 2012; 30:1656-1664.
45. Peterzan MA, Hardy R, Chaturvedi N, Hughes AD. Meta-analysis of dose-response relationships for hydrochlorothiazide, chlorthalidone, and bendroflumethiazide on blood pressure, serum potassium, and urate. Hypertension 2012; 59:1104-1109.
46. Bunker J, Callister W, Chang CL, Server PS. How common is true resistant hypertension. J Hum Hypertens 2011; 25:137-140.